Advertisement

Annals of Hematology

, Volume 97, Issue 6, pp 1097–1099 | Cite as

The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma

  • Takahiro Kobayashi
  • Masatomo Miura
  • Maiko Abumiya
  • Takenori Niioka
  • Shuichi Kanno
  • Naoto Takahashi
Letter to the Editor
  • 423 Downloads

Keywords

Lenalidomide Clarithromycin Pharmacokinetics P-glycoprotein 

Notes

Compliance with ethical standards

All procedures were approved by the Institutional Review Board at Akita University Graduate School of Medicine.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Rossi A, Mark T, Jayabalan D, Christos P, Zafar F, Pekle P, Pearse R, Chen-Kiang S, Coleman M, Niesvizky R (2013) BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. Blood 121(11):1982–1985.  https://doi.org/10.1182/blood-2012-08-448563 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Niesvizky R, Bergsagel PL, Pearse RN, Pekle K A, Lyons LM, Cho HJ, Roboz GJ, Leonard JP, Coleman M (2002) Clarithromycin potentiates the response to dexamethasone in chemotherapy naive multiple myeloma patients: a prospective, sequential, randomized trial. [Abstract] Blood (100) 389bGoogle Scholar
  3. 3.
    Spahn JD, Fost DA, Covar R, Martin RJ, Brown EE, Szefler SJ, Leung DY (2001) Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study. Ann Allergy Asthma Immunol 87(6):501–505.  https://doi.org/10.1016/S1081-1206(10)62264-8 CrossRefPubMedGoogle Scholar
  4. 4.
    Hofmeister CC, Yang X, Pichiorri F, Chen P, Rozewski DM, Johnson AJ, Lee S, Liu Z, Garr CL, Hade EM, Ji J, Schaaf LJ, Benso Jr DM, Kraut EH, Hicks WJ, Chan KK, Chen C-S, Farag SS, Grever MR, Byrd JC, Phelps MA (2011) Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide–CCI-779 interaction via P-glycoprotein. J Clin Oncol 29(25):3427–3434.  https://doi.org/10.1200/JCO.2010.32.4962 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Takahashi N, Miura M, Kameoka Y, Abumiya M, Sawada K (2012) Drug interaction between lenalidomide and itraconazole. Am J Hematol 87(3):338–333.  https://doi.org/10.1002/ajh.22260 CrossRefPubMedGoogle Scholar
  6. 6.
    Miura M, Takahashi N, Kanno S, Kato S, Nara M, Itoh M, Saitoh H, Yoshioka T, Kameoka Y, Fujisjima N, Tagawa H, Hirokawa M, Sawada K (2011) Drug interaction of (S)-warfarin, and not (R)-warfarin, with itraconazole in a hematopoietic stem cell transplant recipient. Clin Chim Acta 412(21):2002–2006.  https://doi.org/10.1016/j.cca.2011.06.035 CrossRefPubMedGoogle Scholar
  7. 7.
    Shida S, Takahashi N, Miura M, Niioka T, Matsumoto M, Hagihara M, Kobayashi T, Abumiya M, Kameoka Y, Fujishima N, Tagawa H, Hirokawa M, Sawada K (2014) A limited sampling model to estimate exposure to lenalidomide in multiple myeloma patients. Ther Drug Monit 36(4):505–509.  https://doi.org/10.1097/FTD.0000000000000034 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Hematology, Nephrology, and RheumatologyAkita University Graduate School of MedicineAkitaJapan
  2. 2.Department of PharmacyAkita University HospitalAkitaJapan
  3. 3.Department of Clinical PharmacotherapeuticsTohoku Medical and Pharmaceutical UniversitySendaiJapan

Personalised recommendations